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Chronic itch is a prevalent and debilitating condition
for which few effective therapies are available. We
harnessed the natural variation across genetically
distinct mouse strains to identify transcripts co-re-
gulated with itch behavior. This survey led to the
discovery of the serotonin receptor HTR7 as a key
mediator of serotonergic itch. Activation of HTR7
promoted opening of the ion channel TRPA1, which
in turn triggered itch behaviors. In addition, acute
itch triggered by serotonin or a selective serotonin
reuptake inhibitor required both HTR7 and TRPA1.
Aberrant serotonin signaling has long been linked
to a variety of human chronic itch conditions, in-
cluding atopic dermatitis. In a mouse model of
atopic dermatitis, mice lacking HTR7 or TRPA1 dis-
played reduced scratching and skin lesion severity.
These data highlight a role for HTR7 in acute and
chronic itch and suggest that HTR7 antagonists
may be useful for treating a variety of pathological
itch conditions.
INTRODUCTION
Chronic itch is a debilitating disorder that results from of a num-
ber of skin diseases such as atopic dermatitis, as well as sys-
temic conditions including kidney failure, cirrhosis, and some
cancers. Although itch from allergy or bug bites is often treatable
with antihistamines, most forms of chronic itch are resistant to
antihistamine treatment (Mollanazar et al., 2015). Further, an
estimated 10%–20% of the population will suffer from chronic
itch at some point in their lifetime (Matterne et al., 2011; Metz
and Sta¨nder, 2010). Consequently, understanding the molecular
basis of chronic itch is of significant clinical interest. Itch signals
are transduced via a subset of primary afferent sensory neurons
that innervate the skin. A number of studies have identified cells
and receptors that transduce acute itch signals (Bautista et al.,
2014; Garibyan et al., 2013; Mollanazar et al., 2015; Ross,
2011). However, the molecular mechanisms underlying the124 Neuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc.development, maintenance, and transmission of chronic itch sig-
nals remain largely unknown. Likewise, a number of unanswered
questions about acute itch transduction persist, including the
peripheral mechanisms by which itch is induced by the prurito-
gen serotonin.
Peripheral serotonin, or 5-hydroxytryptamine (5-HT), is a com-
ponent of the ‘‘inflammatory soup’’ and has been identified as
a potent inducer of itch (Bautista et al., 2014; Hoon, 2015) and
pain (Bardin, 2011; Julius and Basbaum, 2001; Kayser et al.,
2007; Zeitz et al., 2002). Indeed, in humans, aberrant 5-HT
signaling in the skin is linked to itch in atopic dermatitis (Huang
et al., 2004; Soga et al., 2007), as well as in other disorders
including allergy (Liu et al., 2013; Lundeberg et al., 1999), uremia
(Kerr et al., 1992), cholestasis (Schwo¨rer et al., 1995), and
psoriasis (Nordlind et al., 2006). Although numerous studies
have highlighted the importance of 5-HT in acute and chronic
itch (Han et al., 2013; Huang et al., 2004; Imamachi et al.,
2009; Liu et al., 2013; Mishra and Hoon, 2013), the 5-HT receptor
subtypes that transduce serotonergic itch signals have remained
enigmatic.
Here, we examined itch behaviors and sensory neuron gene
expression across genetically distinct mouse strains. We
observed a correlation between acute itch behavior and expres-
sion of the 5-HT receptor, HTR7. This first clue to the function of
HTR7 in the periphery served as motivation for an extensive
characterization of its role in serotonergic and chronic itch. We
found that HTR7 is expressed in a subset of primary afferent sen-
sory neurons that innervate the skin and promote acute itch but
not pain behaviors. HTR7 is functionally coupled to the irritant re-
ceptor TRPA1, and together they trigger neuronal excitation and
mediate acute serotonergic- and SSRI-evoked itch. We also es-
tablished that HTR7 and TRPA1 are keymediators of chronic itch
in a mouse model of atopic dermatitis. Our finding is the first
demonstration of a 5-HT receptor that mediates both acute
and chronic itch in the periphery.
RESULTS
Examining Natural Variation in Itch Behaviors and Gene
Expression
Previous studies have shown that genetically distinct inbred
mouse strains display variable somatosensory behaviors such
Figure 1. A Survey of Mouse Natural Variation Reveals Htr7 as a Candidate Itch Transducer in DRG Neurons
(A) The mouse strains C57BL/6J and DBA/2J display differential scratching behavior to various pruritogens: TSLP, thymic stromal lymphopoietin (15 nM); 5-HT,
5-hydroxytryptamine (1 mM); BAM, bovine adrenal medulla peptide 8-22 (3.5 mM); CQ, chloroquine (40 mM); 48/80, compound 48/80 (4 mM); HIS, histamine
(27 mM). Student’s t test; *p < 0.05; **p < 0.01; n = 4–8/strain. Error bars represent SEM. At bottom, schematic representation of the BXD recombinant inbred
strains from a cross between C57BL/6J and DBA/2J mouse strains.
(B) Heatmap visualization of the 20 genes whose expression in dorsal root ganglia (DRG) neurons correlates most highly with itch behavior (time spent scratching,
30 min) across BXD mouse strains; each row reports normalized gene expression from one strain (white, low relative to gene median; dark blue, high) ordered
based on CQ itch sensitivity (bottom). Black box highlights Htr7. See also Tables S1 and S2.as pain and itch (Green et al., 2006; Nair et al., 2011). We set
out to identify transcripts that were co-regulated with itch
behaviors across such mouse strains. We first surveyed the
effects of a battery of pruritogens in C57BL/6J (BL6) and
DBA/2J (DBA) mice (Figure 1A). As itch is mediated by both his-
tamine-dependent and -independent itch circuits, we examined
a number of pruritogens that target each pathway. Because we
sought to compare responses to a single pruritogen across
strains, rather than between pruritogens, we chose concentra-
tions for each pruritogen that elicited reliable scratching behav-
iors in the literature (Green et al., 2006; Kuraishi et al., 1995,
2000; Liu et al., 2012; Wilson et al., 2011, 2013b). All hista-
mine-independent compounds tested—the anti-malarial drug
chloroquine, compound 48/80, and the endogenous prurito-
gens 5-HT, thymic stromal lymphopoietin (TSLP), and bovine
adrenal medulla peptide 8-22 (BAM 8-22)—evoked more avid
scratching in the DBA strain than in BL6 (Figure 1A). In contrast,
histamine-evoked itch was more avid in the BL6 strain than in
DBA (Figure 1A; Green et al., 2006).
To ask whether these parental itch phenotypes were herita-
ble, we next assayed itch behaviors in a panel of inbred prog-
eny strains from a cross between BL6 and DBA (Taylor et al.,
1973) (BXD; Figure 1A). We were particularly interested in
histamine-independent itch responses because most forms ofchronic itch are histamine independent. We chose to use the
itch response to chloroquine as a representative of all hista-
mine-independent pruritogens, for a number of reasons. First,
chloroquine evokes histamine-independent itch in both mice
and humans (Green et al., 2006; Liu et al., 2009). Second, the
subpopulation of neurons that expresses the chloroquine re-
ceptor MrgprA3 mediates multiple forms of histamine-indepen-
dent acute and chronic itch, and selective activation of these
neurons triggers itch but not pain behaviors (Han et al.,
2013). Finally, given that the DBA parental strain exhibited
stronger itch behaviors to all non-histaminergic pruritogens
tested (even those known to signal via distinct cellular path-
ways; Figure 1A), we hypothesized that this strain harbors
one or more alleles that promote multiple forms of histamine-in-
dependent itch, for which chloroquine could serve as a proxy.
We observed a wide range of itch responses in progeny
strains from the BXD cross upon chloroquine injection (Fig-
ure 1B), far beyond the spread attributable to measurement er-
ror alone (broad-sense heritability = 0.65), reflecting a quantita-
tive relationship between genetic background and this complex
somatosensory behavior.
We considered that the DNA variation across strains that
drove itch behaviors would also perturb expression of many
genes, including some involved in distinct itch pathways. ThisNeuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc. 125
expectation was based on the principle that a naturally occurring
DNA sequence variant underlying a given phenotype (e.g., dis-
ease or behavior) often affects the expression of hundreds of
genes of related but distinct function (Schadt, 2005; Cookson
et al., 2009). Indeed, it is axiomatic that genes of many subtypes,
though of broadly similar biological function, can be co-regu-
lated transcriptionally. For example, nutrient restriction upregu-
lates genes that are protective for starvation as well as those
dispensable for this behavior but required for other related stress
responses (Giaever and Nislow, 2014). We thus hypothesized
that there could be transducers in any of a multitude of itch path-
ways among the transcripts co-regulated with chloroquine itch
across mouse strains. To identify such transcripts, we transcrip-
tionally profiled dorsal root ganglia (DRG), which contain the neu-
rons responsible for detecting itch, touch, and pain stimuli, in
each BXD progeny strain. We identified 72 genes whose expres-
sion correlated positively across strains with itch behavior, and
37 negatively correlated with itch (jrj > 0.55; Figure 1B and Table
S1); this set of transcriptional correlates of itch was enriched
in a number of somatosensory and cell signaling categories,
including 5-HT signaling (Table S2).
HTR7 Is a Candidate Itch Transducer
Among the top transcriptional correlates of chloroquine itch,
we noted two 5-HT receptors, HTR7 and HTR1d. 5-HT has
long been linked to chronic itch and pain (Bardin, 2011; Bautista
et al., 2014; Hoon, 2015; Julius and Basbaum, 2001; Zeitz et al.,
2002), and somatosensory neurons express ten distinct sub-
types of 5-HT receptors (Bardin, 2011; Manteniotis et al., 2013)
with the exact role of each subtype in somatosensation yet
to be defined. We thus singled out for functional characteriza-
tion HTR7, the receptor whose expression was most highly
correlated with itch behavior (Figure 1B). Htr7 expression was
2-fold higher in the most sensitive progeny strain than in the
least responsive progeny (Figure 2A), and 1.3-fold higher in
the more itch-prone DBA parental strain than in BL6 (BL6 =
1,031.67 ± 78.19 reads, DBA = 1,305.00 ± 18.19 reads; p <
0.05; n = 3 mice/strain).
HTR7 Is Expressed and Functional in Sensory Neurons
that Innervate the Skin
Somatosensory ganglia contain an array of neurons that mediate
itch, touch, and pain. We expected that, if HTR7 played a role in
itch transduction, we should observe expression in a subset of
the small-diameter DRG neurons that detect noxious stimuli
and innervate the skin. In validation of our RNA-seq measure-
ments, we detected Htr7 transcripts in human and mouse DRG
with RT-PCR (Figure 2B). Using in situ hybridization, we detected
the Htr7 transcript in 11.2% of DRG neurons, the majority of
which were small-diameter neurons (average size = 17.7 mm;
Figure 2C). Next, we probed hairy skin using antibodies against
HTR7 and TRPA1 and found that HTR7 protein was expressed in
23.6% ± 6.9% of TRPA1-positive fibers that innervate the skin
(Figure 2D). Although we also observed HTR7 immunoreactivity
in the epidermis, such stainingwas non-specific, as it manifested
in both wild-type and HTR7 knockout mice (Figure S1A). We next
used ratiometric calcium imaging to investigate whether HTR7
was functional in cutaneous primary afferent sensory neurons.126 Neuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc.We first labeled cutaneous afferents via intradermal injection
of the retrograde tracer cholera toxin-B-594 (CTB-594) and
cultured dissociated sensory neurons 24 hr post-injection. Appli-
cation of the HTR7-selective agonist, 4-[2-(Methylthio)phenyl]-
N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-iperazinehexanamide
hydrochloride (LP44), to cultured DRG neurons triggered a rise
in intracellular calcium in 8.3% ± 0.76% of labeled cutaneous
afferents (37.9% ± 5.2% of all neurons were labeled red), sug-
gesting that HTR7 is functional in neurons that innervate the
skin (Figure 2E).
The LP44-evoked neuronal response was dose dependent
with an EC50 at 85.7 ± 3.0 mM (Figure S1B). In contrast, LP44
failed to elicit a rise in intracellular calcium in primary mouse ker-
atinocytes (Figure 2F), suggesting that HTR7 is not functional in
keratinocytes. Overall, these data show that HTR7 is expressed
and functional in a subset of small-diameter sensory neurons
that innervate the skin and mediate itch and/or pain.
Previous studies have shown that neurons that transduce
itch and pain signal via the TRPA1 and TRPV1 ion channels (Im-
amachi et al., 2009; Karai et al., 2004; Mishra and Hoon, 2013;
Wilson et al., 2011, 2013a). We found that all LP44-sensitive
neurons were responsive to the TRPA1 agonist allyl isothiocya-
nate (AITC) and to the TRPV1 agonist capsaicin (Figures 3A–
3C). LP44-positive neurons were also sensitive to other prurito-
gens, including 5-HT (100%), chloroquine (63.6%), histamine
(27.3%), and BAM8-22 (13.6%), but not TSLP (Figure 3C). These
data show that HTR7 is functionally expressed in a heteroge-
neous subpopulation of serotonergic neurons that may subserve
distinct roles in itch or inflammation. LP44 also evoked mem-
brane depolarization and action potential firing in DRG neurons
(Figure 3D). Thus, HTR7 activation induces neuronal excitability
in a subset of TRPV1- and TRPA1-positive neurons. To deter-
mine whether HTR7, TRPA1, and TRPV1 are required for
LP44-evoked excitation, we evaluated responses in neurons iso-
lated from mice lacking these receptors. LP44-evoked calcium
responses were significantly attenuated in DRG neurons isolated
from Htr7/ and Trpa1/ mice, but not in Trpv1/ neurons
(Figure 3E). Similar results were observed in trigeminal ganglia
(TG; data not shown). These results suggest that HTR7 is func-
tionally coupled to TRPA1 and that the two receptors work
together to mediate LP44-evoked excitation in a subset of itch
and/or pain neurons.
HTR7 Activates TRPA1 via Adenylate Cyclase Signaling
HTR7 is a Gs-coupled GPCR that activates adenylate cyclase
(AC) via both Ga and Gbg in a variety of cell types (Adham
et al., 1998; Lovenberg et al., 1993; Tang andGilman, 1991). Pre-
vious studies have also shown that both AC and Gbg signaling
activate the ion channel TRPA1 (Schmidt et al., 2009; Wilson
et al., 2011). In sensory neurons, we found that inhibition of AC
and Gbg signaling with 20,30-dideoxyadenosine and gallein,
respectively, attenuated LP44-evoked calcium signals, whereas
U-73122, an inhibitor of PLC signaling, had no effect (Figure 3F).
We next asked whether HTR7 could activate heterologous
TRPA1 channels expressed in HEK293 cells. LP44-evoked cur-
rents were observed in HEK293 cells transfected with both
hHTR7 and hTRPA1, but not in cells expressing hHTR7 alone
(Figures 3G–3I); AITC triggered a similar current of larger
Figure 2. HTR7 Is Expressed in Sensory
Neurons that Innervate the Skin
(A) Htr7 expression in DRG neurons correlates
strongly with CQ itch across BXD strains. Each
point represents one BXD strain.
(B) PCR amplification of Htr7 transcripts shows
expression in mouse and human DRG.
(C) Left: in situ hybridization of an Htr7 probe in
mouse DRG. Scale bar, 100 mm. Middle: a higher
magnification of the region encased by the yellow
box in the left panel. Htr7-positive cell bodies are
highlighted in yellow, Htr7-negative cell bodies in
white. Scale bar, 50 mm. Right: Htr7 is expressed
mostly in small-diameter cells (n = 5 sections, 642
cells).
(D) Immunostaining of hairy skin shows expression
of HTR7 in a subset of TRPA1-positive sensory
neuronal fibers. Left: immunostaining of hairy skin
with antibodies against HTR7 and TRPA1, counter
stained with DAPI. Right: a higher magnification of
region encased by the yellow box in the left panel.
Arrowheads mark HTR7- and TRPA1-positive
neuronal fibers; the arrow marks an HTR7-nega-
tive, TRPA1-positive neuronal fiber. Dotted line
demarcates dermal-epidermal boundary based
on DAPI staining. Scale bar, 10 mm.
(E) Left: retrogradely labeled cutaneous afferents
with cholera toxin subunit B (CTB) were cultured
and LP44 (100 mM) responses were assayed using
calcium imaging. Scale bar, 100 mm. Right: LP44
promotes calcium influx in labeled cutaneous
afferent 1, but not 2.
(F) LP44 does not activate primary mouse kerati-
nocytes; quantification of peak LP44-evoked Ca2+
responses in mouse primary keratinocytes to
vehicle (VEH), LP44, and thapsigargin (THAP).
One-way ANOVA, Tukey-Kramer post hoc test;
ns, p R 0.05; ***p < 0.001. Error bars represent
SEM. See also Figure S1.magnitude in cells expressing both hHTR7 and hTRPA1 (Figures
3G and 3H). Likewise, LP44 evoked significant increases in intra-
cellular calcium in HEK293 cells expressing both HTR7 and
TRPA1, but not in cells expressing either receptor alone (Fig-
ure 3J). HTR7 and TRPA1 together, but neither alone, also
conferred 5-HT sensitivity to HEK293 cells (Figure 3K). Thus,
HTR7 and TRPA1 receptors are functionally coupled and
mediate response to both LP44 and 5-HT.Neuron 87, 124HTR7 Activation Causes Itch but
Not Pain
Somatosensory neurons are a diverse
population that mediates acute and
chronic itch and pain (Bautista et al.,
2014; Ross, 2011). Likewise, 5-HT
signaling in the somatosensory system
has been linked to both itch and pain.
Previous reports have investigated the
role of HTR7 in pain behaviors with mixed
results: several studies have found no
role for HTR7 in promoting acute pain
(Nascimento et al., 2011; Roberts et al.,2004), others found that systemic application of an HTR7 agonist
had a modest attenuating effect on inflammatory pain (Brenchat
et al., 2009, 2012), and most recently, injection of an HTR7
agonist into the anterior cingulate cortex attenuated mechanical
hypersensitivity (Santello and Nevian, 2015). To investigate
whether specific activation of peripheral HTR7 by LP44 triggered
itch and/or pain behaviors, we used the mouse cheek model of
itch, in which pruritic agents elicit scratching with the hindlimb,–138, July 1, 2015 ª2015 Elsevier Inc. 127
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and nociceptive agents cause wiping with the forepaw (LaMotte
et al., 2014). Injection of LP44 into the cheek of wild-type mice
evoked scratching behaviors that were not observed following
vehicle injection (Figure 4A). HTR7 is the sole mediator of
LP44-evoked scratching as pharmacological inhibition (SB-
269970; Figure 4A, gray) or genetic ablation (Figure 4B, red)
of HTR7 significantly attenuated LP44-evoked scratching to
levels similar to vehicle. We also observed significantly more
scratching in the DBA mouse strain than in BL6 (Figure S1C),
mirroring the higher Htr7 expression in DBA sensory ganglia.
Given the requirement of TRPA1 for LP44-evoked signaling in
neurons (Figure 3E), we hypothesized that TRPA1would likewise
be required for LP44-evoked behaviors. Indeed, animals lack-
ing Trpa1, but not Trpv1, exhibited attenuated LP44-evoked
scratching (Figures 4C and 4D). Echoing our finding of differ-
ences between DBA and BL6 mice, we observed some variation
in LP44 response across distinct wild-type strains (compare
wild-type mice in Figures 4B–4D); analysis of any one mutant
strain was thus carried out with respect to its isogenic wild-
type. Htr7 and Trpa1 were required for LP44-evoked itch
in both the cheek and neck itch models in line with the require-
ment of these receptors in LP44-evoked excitability in both
TG and DRG neurons. Taken together, these data show that
both HTR7 and TRPA1 are required for LP44-evoked itch
behaviors.
Does LP44 act on HTR7 and TRPA1 receptors that are ex-
pressed on sensory neurons, or on non-neuronal cells in the
skin to induce itch behaviors? We first asked whether sensory
neurons are required for LP44-evoked itch. To address this
question, we used the TRPV1 agonist, resiniferatoxin (RTX),
which when injected results in defunctionalization of TRPV1-
and TRPV1/TRPA1-positive neurons (Karai et al., 2004; Mishra
and Hoon, 2013; Wilson et al., 2013a). LP44-evoked scratching
was significantly decreased in RTX-treated mice, to levels
observed in vehicle-treated mice (Figure 4E). These findings
show that LP44 induces itch via TRPV1+ sensory neurons but
do not reveal the site of transduction. Previous studies suggestFigure 3. HTR7 Signals through Gbg, Adenylate Cyclase, and TRPA1 t
(A) Fura-2-loaded DRG neurons treated with LP44 (100 mM) and KCl (75mM). Arro
ratio.
(B) Representative trace shows a neuron that responds to LP44 (100 mM), 5-HT
(C) Left: LP44-responsive neurons are all sensitive to 5-HT (100 mM), AITC (100 m
population of chloroquine-sensitive neurons (64%), and smaller subsets overlap w
No overlap is observed in the CQ-insensitive, TSLP-positive population.
(D) Current-clamp recording showing action potential firing evoked by LP44 (100
(E) Percentage of calcium responders to LP44 (100 mM) is reduced in neurons from
(F) Percentage of calcium responders to LP44 (100 mM) is reduced in neurons pretr
or the Gbg blocker gallein (GAL, 100 mM), but not the PLC blocker, U73122 (U7, 1
hoc test; ns, pR 0.05; **p < 0.01; n = 3 mice/genotype or treatment, nR 200 c
(G) An inward current is evoked by LP44 (100 mM) in HEK293 cells transfected w
(H) Representative current-voltage trace of HEK293 cell transfected with HTR7 a
AITC (100 mM).
(I) HTR7 and TRPA1 are both required for LP44-evoked currents in transfected H
treatment) in HEK293 cells transfected as in (G). Each point represents one cell.
(J) HTR7 and TRPA1 are both required for LP44-evoked calcium influx in transfe
cells transfected with pcDNA3 (CON), HTR7, and/or TRPA1.
(K) HTR7 and TRPA1 are both required for 5-HT-evoked calcium influx in transfec
HEK293 cells transfected with pcDNA3 (CON), HTR7, and/or TRPA1. One-way
fections. Error bars represent SEM.that HTR7 and TRPA1 may be expressed in mast cells (Idzko
et al., 2004; Oh et al., 2013), which release a variety of com-
pounds that can activate sensory neurons and trigger itch.
Thus, we next asked whether HTR7-evoked itch is mast cell
dependent. We compared HTR7-evoked itch behaviors in a
mouse strain lacking mast cells (KitW-sh) to wild-type controls
(Figure 4F). LP44 triggered considerable scratching in both
strains, suggesting that HTR7-mediated responses do not
require mast cells, or pruritogens/cytokines released by mast
cells, to trigger itch behaviors. TRPA1 has also been proposed
to be expressed in keratinocytes; though whether it is expressed
and functional inmouse keratinocytes remains to be determined.
However, LP44-evoked itch behaviors in K14-Cre;Trpa1fl/fl mice
and Trpa1fl/fl mice were indistinguishable (Figure 4G), indicating
that TRPA1 in keratinocytes does not underlie this phenotype;
these findings are consistent with our observation that keratino-
cytes exhibited no calcium response to LP44 (Figure 2F). Overall
these data show that neither mast cells nor TRPA1-mediated
signaling in keratinocytes are required for acute itch triggered
by HTR7 activation and suggest that HTR7 in sensory neurons
may mediate LP44-evoked itch.
We next sought to establish whether activation of HTR7 could
elicit pain. Unlike 5-HT, which has been shown to trigger
both itch-evoked scratching and nocifensive wiping behaviors
(Akiyama et al., 2010), we observed no wiping in LP44-injected
animals (Figure 4H). Likewise, injection of LP44 into the hindpaw
did not cause thermal hypersensitivity, in stark contrast to 5-HT
injection, which induced a significant decrease in the thermal
withdrawal latency (Figure 4I). Overall, these data make clear
that acute activation of HTR7 by LP44 evokes itch but not pain
behaviors.
HTR7 Mediates Serotonergic Itch
We next set out to evaluate the role of HTR7 in serotonergic itch.
Most studies measuring 5-HT-evoked itch and pain behaviors
have used relatively high doses (1–94 mM; Akiyama et al.,
2010; Kuraishi et al., 2000; Nojima and Carstens, 2003; Zeitzo Promote Neuronal Excitation
whead depicts an LP44-responsive neuron. Pseudocolor bar represents Fura-2
(100 mM), and allyl isothiocyanate (AITC; 100 mM).
M), and capsaicin (1 mM). Right: the majority of these neurons overlap with the
ith chloroquine/BAM8-22-sensitive (6%) or histamine-sensitive neurons (27%).
mM) in a representative DRG neuron. Inset, single action potential.
Htr7/ and Trpa1/mice, but not Trpv1/mice, relative to wild-type (WT).
eated with the adenylate cyclase blocker 20,30-dideoxyadenosine (DDA, 50 mM)
mM), relative to vehicle treatment (VEH). One-way ANOVA, Tukey-Kramer post
ells/genotype or treatment.
ith HTR7 and TRPA1 but not with HTR7 alone using voltage-clamp recording.
nd TRPA1 in the absence (background, BKG) or presence of LP44 (100 mM) or
EK cells; quantification of LP44-induced peak currents (normalized to vehicle
Fisher’s exact test; *p < 0.05; n = 16 cells/transfection.
cted HEK cells; quantification of peak LP44-evoked Ca2+ response in HEK293
ted HEK cells; quantification of peak 5-HT-evoked (100 mM) Ca2+ response in
ANOVA, Tukey-Kramer post hoc test; ns, pR 0.05; **p < 0.01; n = 3-5 trans-
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Figure 4. HTR7 Triggers Robust Acute Itch
Behaviors, but Not Pain
(A) LP44 (2 mM), but not vehicle (VEH; 20 ml, 2%
DMSO in PBS) injection induces scratching be-
haviors in the cheekmodel of itch. This response is
blocked by the pre-injection of HTR7 antagonist
SB-269970 (SB, 5 mM).
(B) Scratching evoked by LP44 injection is atten-
uated in Htr7/ mice relative to Htr7+/+ wild-type
mice (WT).
(C) Scratching evoked by LP44 injection is atten-
uated in Trpa1/ mice relative to Trpa1+/+ wild-
type mice (WT).
(D) LP44-evoked itch behavior is similar in Trpv1+/+
(WT) and Trpv1/ mice.
(E) TRPV1-positive neuronal ablation by
resiniferatoxin (RTX) eliminates LP44-evoked
scratching.
(F) LP44-evoked itch behaviors are similar in mast
cell deficient mice (KitW-sh) and wild-type control
mice (WT).
(G) LP44-evoked itch behaviors are similar in
K14-Cre;Trpa1fl/fl mice and Trpa1fl/fl control mice.
(H) LP44 (2 mM) does not evoke wiping behavior,
while 1 mM 5-HT causes robust wiping. VEH,
vehicle.
(I) Thermal hypersensitivity in mice injected with
5-HT (10 mM) and LP44 (2 mM). One-way ANOVA,
Tukey-Kramer post hoc test; ns, p R 0.05; *p <
0.05; **p < 0.01; ***p < 0.001; n = 5–9 mice/ge-
notype/behavior. Error bars represent SEM. See
also Figure S1.et al., 2002). Yet the elevated 5-HT levels in chronic itch patients
and in mouse models have been measured to be in the micro-
molar range (Kerr et al., 1992; Liu et al., 2013; Lundeberg et al.,
1999; Soga et al., 2007). To test for distinctions between these
two 5-HT dose regimes, we evaluated the behavioral effects of
each in mice. Upon injection of 1 mM 5-HT in wild-type animals,
we observed both scratching and wiping behaviors (Figures 5A
and 5B), consistent with previous reports (Akiyama et al., 2010;
Moser and Giesler, 2014). By contrast, injection of 100 mM
5-HT in wild-type mice elicited robust scratching but little wiping
(Figures 5A and 5B). Together, these data show that 5-HT has
distinct physiological effects at different concentrations and
that 100 mM 5-HT preferentially activates itch pathways. HTR7
does not mediate behavioral responses to high 5-HT levels, as
1mM5-HT evoked itch and pain behaviors inHtr7/mice indis-
tinguishable from those of wild-type animals (Figure 5C, red).
However, the itch-specific effects of 100 mM 5-HT were medi-
ated by HTR7: Htr7/animals exhibited a significant decrease130 Neuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc.in itch behavior, to levels on par with
vehicle injection (Figure 5D, red versus
white). Given that both HTR7 and TRPA1
were required for LP44-evoked signaling
in neurons and HEK293 cells (Figures 3E
and 3J–3K), we hypothesized that
TRPA1 would likewise be necessary
for serotonergic itch. Indeed, Trpa1/
animals displayedsignificantly decreaseditch behaviors as compared to wild-type littermates, in response
to 100 mM 5-HT (Figure 5E, blue).
Previous studies have shown that SSRIs increase 5-HT levels
(Blardi et al., 2002) and that elevated 5-HT levels promote itch
sensations and scratching in humans (Cederberg et al., 2004;
Rausl et al., 2013). Some studies have shown that SSRIs can
alleviate certain forms of chronic itch and pain (Anjaneyulu and
Chopra, 2004; Browning et al., 2003; Zylicz et al., 2003), while
others have reported that SSRIs can induce severe itch and
rash (Cederberg et al., 2004; Sannicandro et al., 2002; Warnock
and Morris, 2002; FDA, 2014). We thus asked whether intrader-
mal injection of SSRIs increased local 5-HT levels to trigger
itch behaviors in mice. Injection of the SSRI sertraline induced
a rapid increase in skin 5-HT (Figure 5F) and induced itch-
evoked scratching in wild-type animals (Figure 5G). Mirroring
the results of 100 mM 5-HT injection (Figures 5D and 5E),
we observed a significant attenuation of SSRI-evoked scratch-
ing in Htr7/ and Trpa1/ mice as compared to wild-type
littermates (Figure 5H; no significant differences in behavior were
observed between Htr7+/+ and Trpa1+/+ mice). Thus, HTR7 and
TRPA1 together mediate some forms of serotonergic and
SSRI-mediated itch.
We also examined the contribution of HTR7 to itch behaviors
to a number of non-serotonergic pruritogens. Histamine, com-
pound 48/80 and chloroquine all induced comparable itch be-
haviors in Htr7/ and wild-type mice (Figure 5I). Htr7/ mice
also exhibited normal radiant heat- and AITC-evoked pain be-
haviors (Figures 5J and 5K). Overall, our findings make clear
that HTR7 is a mediator of serotonergic itch, but not other forms
of itch or pain.
HTR7 and TRPA1 Are Required for the Development of
Chronic Itch
Altered 5-HT signaling is associated with a variety of chronic itch
conditions in humans, including atopic dermatitis (Huang et al.,
2004; Soga et al., 2007). We next asked whether HTR7 plays a
role in chronic itch in vivo, using amousemodel of atopic derma-
titis. Previous studies have shown that topical treatment with a
vitamin D analog, MC903, induces an atopic dermatitis-like
phenotype that includes secretion of the atopic dermatitis cyto-
kine, TSLP, immune cell infiltration, skin hyperplasia, and the
development of eczematous lesions (Li et al., 2006). However,
several additional hallmarks of human atopic dermatitis (AD),
including high 5-HT levels in the skin and intense itch-evoked
scratching, have yet to be quantified in this mouse model. To
further validate this mouse model of human atopic dermatitis,
we used a treatment course of 7 consecutive days of topical
application ofMC903 to themouse cheek andmonitored itch be-
haviors for a total of 12 days; we also measured 5-HT levels and
skin lesion severity immediately following the final treatment.
Consistent with previous reports (Li et al., 2006), we found that
wild-type mice treated with MC903 developed eczematous-like
lesions that worsened over time in redness (erythema), dryness
(xerosis), and scabbing (excoriation; Figures 6A and 6B). As
is true for human atopic dermatitis patients, we found that
MC903-treated mice displayed high levels of 5-HT in eczema-
tous skin (Figure 6C), concomitant with scratching behaviors
that began on the third day of treatment and increased in inten-
sity, even after the 7-day treatment period (Figure 6D). These
data show for the first time that the itch behaviors and 5-HT
levels associated with human atopic dermatitis are recapitulated
in this atopic dermatitis model.
Htr7/mice treated withMC903 exhibited less severe lesions
and scratched significantly less than the wild-type strain across
the entire 12-day experiment (Figures 6B and 6D, red). Consis-
tent with the requirement for TRPA1 in HTR7-evoked acute
itch (Figure 3H), lesion severity and scratching were also signifi-
cantly reduced in Trpa1/ mice (Figures 6B and 6D, blue). No
significant differences in itch behavior or lesion severity were
observed between Htr7+/+ and Trpa1+/+ wild-type animals of
each strain and thus we combined all data for comparison to
knockout animals. Previous studies have implicated HTR7 in im-
mune cell signaling (Idzko et al., 2004), which may contribute to
5-HT release in the skin; in the AD model, we found that 5-HT
levels in eczematous skin isolated from Htr7/ and Trpa1/
mice were indistinguishable from those of wild-type mice (Fig-ure 6C, red). Thus, HTR7 and TRPA1 are not required for the
release of 5-HT in atopic dermatitis skin. Taken together, our
data identify HTR7 and TRPA1 as key molecular determinants
of atopic dermatitis (Figure 7).
DISCUSSION
In this work, we have taken advantage of natural variation in itch
behavior in mice and gene expression to identify novel molecular
determinants of itch in primary afferent sensory neurons. Many
of the genes that we have found to be co-regulated with itch
behavior have already been implicated in somatosensation,
including Htr1d (Ahn and Basbaum, 2006; Tepper et al., 2002),
Scn8a (Xie et al., 2013), and Ano1 (Cho et al., 2012). However,
a number of novel genes were also identified, many of which
may represent new candidate itch transducers. We focused on
the 5-HT receptor, HTR7, and established its role as a key trans-
ducer of serotonergic acute and chronic itch.
In the periphery, 5-HT can act as an algogen to trigger acute
pain or pain hypersensitivity (Bardin, 2011; Julius and Basbaum,
2001; Kayser et al., 2007; Zeitz et al., 2002), a pruritogen to
trigger itch-evoked scratching, rash, or wheal (Imamachi et al.,
2009; Kalz and Fekete, 1960; Nojima and Carstens, 2003), or in
some cases, both itch and pain (Akiyama et al., 2010; Moser
and Giesler, 2014). A variety of 5-HT receptor subtypes are ex-
pressed in primary afferent sensory neurons, with HTR1–3 being
the best studied. Pharmacological and genetic ablation studies
have shown that HTR1a, HTR1b, HTR2a, HTR2b, and HTR3a
mediate some forms of acute and inflammatory pain transmis-
sion (Abbott et al., 1996; Kayser et al., 2007; Lin et al., 2011; No-
jima and Carstens, 2003; Van Steenwinckel et al., 2008; Zeitz
et al., 2002). Pharmacological studies have also implicated pe-
ripheral HTR2a, HTR2b, and HTR3 receptors, and central
HTR1a receptors in itch (Bonnet et al., 2008; Imamachi et al.,
2009; Kyriakides et al., 1999; Liu et al., 2013; Zhao et al.,
2014), but to date there has been no genetic evidence for any
5-HT receptor in transducing serotonergic itch signals in primary
afferent neurons. We have used genetic and pharmacological
tools to show that HTR7 plays a selective role in acute seroto-
nergic and atopic dermatitis itch, but not pain. Our results
augment the previous characterization of HTR7 in the CNS in
circadian rhythm function (Glass et al., 2003; Lovenberg et al.,
1993), central thermoregulation (Hedlund et al., 2003), neuroen-
docrine function (Jørgensen, 2007; Kim et al., 2013), migraine
(Hedlund, 2009), and antinociception (Bardin, 2011; Santello
and Nevian, 2015).
HTR7 Mediates Acute Serotonergic Itch
Our data implicate HTR7 as a key component of the 5-HT itch
pathway. In designing methods to assay 5-HT-evoked itch,
we found that different concentrations of 5-HT evoked distinct
behaviors. Micromolar 5-HT concentrations triggered itch
but not pain behaviors, while millimolar concentrations trig-
gered both itch and pain. Most experimental analyses of
5-HT-evoked behavior have used millimolar concentrations
(1–94 mM; Akiyama et al., 2010; Kuraishi et al., 2000; Nojima
and Carstens, 2003; Zeitz et al., 2002), which are significantly
higher than the 5-HT levels measured in chronic itch conditionsNeuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc. 131
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(Kerr et al., 1992; Liu et al., 2013; Lundeberg et al., 1999; Soga
et al., 2007) and thus may not target physiologically relevant
sites and 5-HT receptor subtypes. Our results make clear
that HTR7 is required for itch behaviors evoked by 5-HT at
100 mM, but not for itch and pain at 1 mM concentrations.
These findings suggest that HTR7 may be preferentially acti-
vated by low 5-HT levels, which dovetail with studies showing
that HTR7 has the highest affinity for 5-HT among HTR family
members (Vanhoenacker et al., 2000). A role for HTR7 in only a
subset of 5-HT-evoked behaviors under particular conditions,
rather than all 5-HT responses, is not surprising given that
many 5-HT receptors are expressed in sensory neurons (Bar-
din, 2011; Manteniotis et al., 2013) and that HTR7 is expressed
in only 35% of the 5-HT-positive neuronal population. The
emerging picture is thus one of specific physiological re-
sponses to different doses of 5-HT that are mediated by
distinct molecular and cellular mechanisms, with HTR7 medi-
ating itch at 5-HT levels comparable to those measured in
chronic itch skin.
HTR7 Mediates Acute SSRI-Evoked Itch
In analyzing the role of HTR7 in serotonergic itch, we also exam-
ined itch behaviors in response to injection of the SSRI sertraline
in the cheek model of itch. SSRI induced an increase in local
5-HT levels and a concomitant increase in scratching behaviors
in mice; HTR7 was required for SSRI-evoked itch behaviors. An
estimated 2%–4% of human patients report itch, rash, and other
related skin conditions as a side effect of taking SSRIs (Cederberg
et al., 2004; Sannicandro et al., 2002; FDA, 2014). As HTR7 is also
expressed in human primary afferent neurons (Figure 2B), it is
tempting to speculate that antagonists may attenuate SSRI-
evoked itch inhumans.Paradoxically,SSRIscanalsopartially alle-
viate some forms of chronic itch (Anjaneyulu and Chopra, 2004;
Browning et al., 2003; Zylicz et al., 2003). Themechanisms under-
lying this dual role for SSRIs in alleviating and causing itch in hu-
mans are unknown; it will be interesting to determine whether
they involve different 5-HT signaling molecules between normal
and chronic itch patients, or differential targeting of peripheral
versus central targets (Browning et al., 2003).
HTR7 Couples to the Irritant Receptor TRPA1
Previous studies showed that serotonergic itch is mediated by a
subset of TRPV1-expressing neurons, though functional TRPV1Figure 5. HTR7 Is Required for the Detection of 5-HT-Dependent Acut
(A) 5-HT (100 mM and 1 mM) but not vehicle injection (VEH; 20 ml, PBS) causes r
(B) Injection of 1 mM but not 100 mM 5-HT evokes wiping behaviors.
(C) Scratching behaviors evoked by 1 mM 5-HT are similar between Htr7+/+ (WT
(D) Scratching behaviors evoked by 100 mM 5-HT are significantly attenuated in
(E) Scratching behaviors evoked by 100 mM 5-HT are reduced in Trpa1/ comp
(F) Skin 5-HT levels increase after injection with the selective serotonin reuptake
(G) Time course of cumulative scratching behavior to sertraline (100 mM) follows th
shown in (F).
(H) Htr7/ and Trpa1/ mice show significant decreases in scratching behavio
(I) Chloroquine (CQ, 40 mM), compound 48/80 (48/80, 4 mM), and histamine (HIS,
mice.
(J) There is no difference in acute heat sensitivity between Htr7+/+ (WT) and Htr7
(K) AITC application (10% inmineral oil) evokes similar nocifensive behaviors inHt
pR 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; n = 5–9 mice/genotype/behavior. Eion channels were dispensable for itch behaviors (Imamachi
et al., 2009). Thus, the receptors and downstream signaling
pathways responsible for 5-HT itch transduction were unknown.
Our results establish TRPA1 as the transduction channel
required for HTR7-mediated acute serotonergic and SSRI-
evoked itch behaviors, echoing the known role for TRPA1 in
other forms of non-histaminergic itch (Cevikbas et al., 2014;
Liu et al., 2013; Oh et al., 2013; Wilson et al., 2011, 2013a,
2013b). Furthermore, we found that HTR7 activation of TRPA1
required functional adenylate cyclase (Figure 3), consistent
with previous studies showing that HTR7 is a Gas-coupled
GPCR that stimulates adenylate cyclase and cAMP production
and that TRPA1 activity is regulated by AC and cAMP in sensory
neurons (Schmidt et al., 2009). Interestingly, TRPA1 does not
couple to all HTRs, as activation of HTR2 by a-methyl 5-HT trig-
gers itch and pain behaviors independent of TRPA1 (Liu et al.,
2013; Schmidt et al., 2009; Wilson et al., 2011). Overall, our
data further highlight the importance of TRPA1 in mediating
non-histaminergic itch.
Do HTR7 and TRPA1 Receptors Act in Neurons to
Mediate Itch Behaviors?
HTR7 and TRPA1 expression have been reported in a variety of
neurons in the CNS and non-neuronal cells in the skin (Bayer
et al., 2007; Idzko et al., 2004; Kwan et al., 2009). Our study pro-
vides several lines of evidence that HTR7 in somatosensory neu-
rons mediates itch behaviors. First, we found that HTR7 activa-
tion in mast cell-deficient mice evokes a normal itch response.
Second, primary mouse and human keratinocytes do not ex-
press functional HTR7 receptors. Third, K14-Cre;Trpa1fl/fl mice
and Trpa1fl/fl mice displayed similar HTR7-evoked itch re-
sponses. Fourth, neuronal ablation of TRPV1-expressing neu-
rons resulted in a dramatic decrease in itch response evoked
by HTR7 activation. Finally, HTR7 functions in the subset of the
MrgprA3 population of neurons (Figure 2) that have proven to
be indispensable in itch but not pain (Han et al., 2013). However,
5-HT is well known to play important roles in modulating itch and
pain signal transmission at multiple levels in the CNS. Indeed,
pharmacological activation of HTR7 in the forebrain has been
recently shown to reduce neuropathic mechanical pain (Santello
and Nevian, 2015). Also, 5-HT acts on a variety of immune and
other non-neuronal cells to modulate itch and inflammation
(Idzko et al., 2004; Soga et al., 2007). Thus, our findings usinge Itch
obust scratching in the cheek model of itch.
) and Htr7/ mice.
Htr7/ versus Htr7+/+ (WT) mice. VEH; 20 ml, PBS.
ared to Trpa1+/+ (WT) mice.
inhibitor (SSRI), sertraline (100 mM). One-way ANOVA, ***p < 0.001.
e time-dependent increase in skin 5-HT levels following sertraline injection, as
rs compared to wild-type (WT) mice following sertraline injection (100 mM).
27 mM) injection evokes similar itch behaviors in both Htr7+/+ (WT) and Htr7/
/ mice.
r7+/+ (WT) andHtr7/mice. One-way ANOVA, Tukey-Kramer post hoc test; ns,
rror bars represent SEM.
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Figure 6. HTR7 Is Required for the Develop-
ment of Chronic Itch in a Model of Atopic
Dermatitis
(A) Representative images of skin isolated from
wild-type (WT), Htr7/, and Trpa1/ mice
treated topically with vehicle control (CON; 20 ml
100% ethanol) or the vitamin D analog, MC903 for
the induction of atopic dermatitis (AD; 200 mM).
(B) Atopic dermatitis lesion severity scores in mice
treated with MC903 or vehicle (as described in A).
(C) The AD model triggers an increase in the
concentration of 5-HT-treated skin isolated from
WT, Htr7/, and Trpa1/ mice. One-way
ANOVA, Tukey-Kramer post hoc test; ns, p R
0.05; *p < 0.05; **p < 0.01; ***p < 0.001; n = 5/ge-
notype/treatment.
(D) Scratching behavior during and after VITD
treatment is attenuated in Htr7/ and Trpa1/
mice. ANOVA for multivariate linear models; ***p <
0.001; n = 10/genotype. Error bars represent SEM.the global HTR7 knockout do not exclude a role for HTR7 outside
primary afferent neurons. Future studies using tissue-specific
knockout mice will determine the contributions of sensory neu-
rons and other cell types to acute and chronic itch.
HTR7 and TRPA1 Are Both Required for Development of
Atopic Dermatitis
In addition to our study of acute serotonergic itch, we also exam-
ined the role of HTR7 and TRPA1 in a mouse model of atopic
dermatitis, motivated by the well-known links between 5-HT
and itch in this condition (Huang et al., 2004; Soga et al.,
2007). Our results revealed for first time that the MC903-induced
mouse model of atopic dermatitis recapitulates the dysregula-
tion of 5-HT in the skin, and the itch behaviors, characteristic
of the human disorder (Huang et al., 2004). In addition, our134 Neuron 87, 124–138, July 1, 2015 ª2015 Elsevier Inc.mouse model is the first in which sponta-
neous itch behaviors manifest in the
absence of a daily skin treatment: we
observed itch behaviors that persisted
5 days after the last skin treatment, es-
tablishing this paradigm as a model of
chronic rather than acute itch. We found
that HTR7- and TRPA1-deficient mice
both displayed less severe skin lesions
and scratched significantly less than
wild-type mice (Figure 6D). However,
these mutant animals displayed elevated
levels of 5-HT in atopic dermatitis skin,
similar to levels observed in wild-type
(Figure 6C). Thus, HTR7 and TRPA1 are
required for the detection, rather than
the release of 5-HT under atopic derma-
titis-like conditions.
When considered in light of previous
studies, our data support a dual role for
TRPA1 in atopic dermatitis. First, when
co-expressed with the TSLP receptor,
TRPA1 acts as a transducer of TSLP-evoked itch and inflammation (Wilson et al., 2013b). Second,
when co-expressed with HTR7, TRPA1 acts as a transducer of
5-HT-evoked itch. We also highlight the importance of 5-HT
signaling in the pathology of atopic dermatitis. Patients with se-
vere atopic dermatitis eventually progress to develop asthma
and allergic rhinitis, in a process known as the ‘‘atopic march’’
(Spergel and Paller, 2003). It is notable that elevated 5-HT levels
are also linked to asthma (Bayer et al., 2007), and future studies
will elucidate how TRPA1-expressing neuronal subtypes orches-
trates the progression of atopic diseases.
Animals lacking Htr7 and Trpa1 still exhibited a residual
degree of eczematous skin lesions and itch behaviors in the
atopic dermatitis model. Thus, an important question is the iden-
tity of the other molecular players required for the complete
development and/or maintenance of atopic dermatitis. Such
Figure 7. Schematic Diagram Depicting the Putative Roles of HTR7
and TRPA1 Signaling in Acute and Chronic Itch
Model by which increased 5-HT levels in the skin, triggered by direct injection
of 5-HT, SSRI administration, or atopic dermatitis activates the 5-HT receptor,
HTR7. HTR7 in turn signals to adenylate cyclase via Ga and Gbg, to
open TRPA1 ion channels, promote neuronal depolarization and action
potential firing, and ultimately trigger itch-evoked scratching.determinants may include TSLP, given its upregulation in the
human disease and the atopic dermatitis mouse model (Li
et al., 2006), and its activity in sensory neurons that promotes
itch behaviors (Wilson et al., 2013b). Interestingly, another
5-HT receptor co-regulated with itch, Htr1d (Figure 1B), has
been previously implicated in inflammatory pain (Ahn and Bas-
baum, 2006; Tepper et al., 2002) and is also a compelling candi-
date mediator of atopic dermatitis and itch. Moreover, numerous
inflammatory mediators are released in atopic dermatitis in addi-
tion to 5-HT and TSLP (Brandt and Sivaprasad, 2011), whose
mechanisms have yet to be revealed.
Despite these complexities, our data clearly show that HTR7
and TRPA1 are key mediators of serotonergic acute and chronic
itch. Aside from AD, a variety of human chronic itch disorders are
linked to 5-HT. It is likely, therefore, that HTR7 antagonists may
prove to be useful for the selective attenuation of itch that results
from these pathological conditions.
EXPERIMENTAL PROCEDURES
RNA-Seq Analysis
We mapped RNA-seq reads from the DRG of each BXD strain to the DBA/2J
andC57BL/6J using Tophat. HTSeqwas used to sum the total read counts per
gene. Read counts were normalized with the EDASeq package in R using the
upper-quartilemethod. Gene ontology enrichment analysis was performed us-
ing the topGO package in R. Information regarding analyses packages is avail-
able in the Supplemental Experimental Procedures. All expression data have
been deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo).
Histology
Histology on skin and in situ hybridization on DRG was carried out as previ-
ously described (Gerhold et al., 2013).
Cell Culture
Cell culture and transfection was carried out as previously described (Wilson
et al., 2011). Cholera toxin subunit B, Alexa Fluor 594 conjugate (Life Technol-
ogies) was used for retrograde labeling of cutaneous afferent neurons.
Electrophysiology
Electrophysiology was performed as previously described (Wilson et al.,
2013b). Whole-cell recordings in transfected cells were performed using the
Port-a-patch system (Brueggemann et al., 2004) (Nanion Technologies).Calcium Imaging
Ca2+ imaging experiments were carried out as previously described (Wilson
et al., 2011). Image analysis and statistics were performed using Igor Pro
(WaveMetrics).
Behavioral Studies
Htr7/ mice were obtained from Jackson Laboratory, Trpv1/ and
Trpa1/ mice were described previously (Bautista et al., 2006; Caterina
et al., 2000), and K14-Cre;Trpa1fl/fl mice were provided by Cheryl Stucky.
Behavioral experiments were performed as previously described (Wilson
et al., 2011). All experiments were performed under the policies and recom-
mendations of the International Association for the Study of Pain and
approved by the University of California, Berkeley Animal Care and Use
Committee.
Atopic Dermatitis Model
MC903 (R&D Systems) was applied to the mouse cheek once per day, for
7 days. Character of lesion scoring was adapted from previous studies (Hamp-
ton et al., 2012; Liu et al., 2013; Yun et al., 2011).
Statistical analysis
The following statistical tests were used where appropriate: Student’s t test,
one-way ANOVA, and ANOVA for multivariate linear models.
ACCESSION NUMBERS
The accession number for the expression profiling of dorsal root ganglia in
BXD mouse strains is GEO: GSE69374.
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Supplemental Information includes Supplemental Experimental Procedures,
one figure, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2015.05.044.
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